CAMBRIDGE, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at three investor conferences in September:
- Citi's 11th Annual Biotech Conference on Thursday, September 8 at 8:00 a.m. ET in Boston;
- Rodman & Renshaw 18th Annual Healthcare Conference on Monday, September 12 at 12:30 p.m. ET in New York City; and,
- Morgan Stanley Global Healthcare Unplugged Conference (fireside chat format) on Tuesday, September 13 at 4:05 p.m. ET in New York City.
Replays of the webcasts of the presentations can be accessed at the investor section of http://www.epizyme.com.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics for people with cancer. Epizyme has built a proprietary product platform to create small molecule inhibitors of chromatin modifying proteins (CMPs), such as histone methyltransferases (HMTs). CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com.
Investors and Media Contact: Julie DiCarlo Epizyme, Inc. firstname.lastname@example.org (617) 401-0721